Core Viewpoint - The company reported a revenue increase of approximately 3.7% year-on-year for the first half of 2025, driven by sales of coated stents and left atrial appendage occluders, despite a significant decline in net profit due to non-recurring items [1] Financial Performance - Revenue for the first half of 2025 was approximately 677 million, an increase of about 3.7% year-on-year [1] - Gross profit was approximately 498 million, representing a year-on-year decrease of about 3.4% [1] - Profit attributable to shareholders was 55.074 million, a significant decrease of 73.21% year-on-year [1] - Earnings per share were 1.3 cents [1] Margin Analysis - Gross margin decreased by 5.3 percentage points year-on-year to approximately 73.6% [1] - The decline in gross margin was attributed to the impact of centralized procurement policies, which led to a decrease in sales prices for certain products in specific regions, as well as changes in the sales mix [1]
先健科技公布中期业绩 公司拥有人应占溢利5507.4万元 同比减少73.21%